633 results on '"Check JH"'
Search Results
2. Dextroamphetamine sulfate treatment eradicates long-term chronic severe headaches from temporomandibular joint syndrome - a case that emphasizes the role of the gynecologist in treating headaches in women
- Author
-
Check Jh
- Subjects
Gynecology ,medicine.medical_specialty ,Sympathetic nervous system ,business.industry ,Pelvic pain ,Dextroamphetamine ,Obstetrics and Gynecology ,Brain tissue ,stomatognathic diseases ,medicine.anatomical_structure ,stomatognathic system ,Reproductive Medicine ,Temporomandibular joint syndrome ,Anesthesia ,medicine ,Temporomandibular Joint Dysfunction Syndrome ,medicine.symptom ,Headaches ,Dextroamphetamine Sulfate ,business ,medicine.drug - Abstract
PURPOSE To test sympathomimetic amine therapy on another type of chronic headache syndrome--headaches from temporal mandibular joint (TMJ) syndrome. MATERIALS AND METHODS A woman with 20 years of severe daily pain from TMJ refractory to all therapies was treated with dextroamphetamine sulfate. RESULTS The woman showed immediate 100% relief from sympathomimetic amine treatment saving her from an expensive jaw breaking operation that was only given a slight chance of helping. CONCLUSIONS Unfortunately most treating physicians are unaware of this defect of sympathetic nervous system hypofunction leading to the absorption of toxins, which when it involves brain tissue, leads to severe headaches. Thus, the gynecologist who is aware of this syndrome because sympathetic nervous system hypofunction is the most common cause of pelvic pain, may need to intervene in women with chronic headaches, even TMJ.
- Published
- 2016
3. Correlation of ImmunoBead® and ImmunoSphere™ Immunoglobulin G (IGG) tests on detecting antisperm antibody (ASA) on sperm
- Author
-
Check Jh and Bollendorf A
- Subjects
Correlation ,Reproductive Medicine ,biology ,business.industry ,Immunology ,biology.protein ,Obstetrics and Gynecology ,Medicine ,Immunoglobulin test ,Antibody ,business ,Sperm ,Immunoglobulin G - Abstract
PURPOSE To determine the correlation with detection of antibody on sperm by a new ImmunoSphere™ Immunoglobulin test vs. ImmunoBeads®. MATERIALS AND METHODS A sampling of sperm tested for antisperm antibody (ASA) tested by direct Immunobead? assay with levels varying from zero to 100% were compared to the percentage of sperm positive for ASA by a new test using immunospheres. RESULTS The correlation was not perfect but, in general, there was good correlation. CONCLUSION Now that the manufacturer is curtailing the manufacture of immunobeads, it is comforting to see a good correlation with immunospheres.
- Published
- 2016
4. Marked improvement of pain from long term fibromyalgia with dextroamphetamine sulfate in a woman who failed to improve with conventional pharmacologic treatment
- Author
-
Check Jh and Cohen R
- Subjects
business.industry ,Pelvic pain ,Obstetrics and Gynecology ,Interstitial cystitis ,Chronic fatigue ,medicine.disease ,Pharmacological treatment ,Reproductive Medicine ,Edema ,Fibromyalgia ,Anesthesia ,Hyperalgesia ,medicine ,medicine.symptom ,Dextroamphetamine Sulfate ,business - Abstract
PURPOSE To determine if treatment with the sympathomimetic amine dextroamphetamine sulfate, which has been so effective in treating a variety of pain syndromes, including severe pelvic pain and interstitial cystitis in women with the sympathetic neural hyperalgesia edema syndrome would also mitigate pain from fibromyalgia which was resistant to multiple therapies. MATERIALS AND METHODS Dextroamphetamine sulfate extended release capsules once daily was gradually increased to 25 mg per day in a woman with treatment resistant fibromyalgia of 20 years duration. RESULTS Within a short time, the woman experienced dramatic relief of pain. Furthermore, her edema improved resulting in a 27 pound weight loss and her chronic fatigue improved. CONCLUSIONS Fibromyalgia can be effectively treated with an innocuous dose of dextroamphetamine sulfate.
- Published
- 2014
5. Marked improvement of the autoimmune syndrome associated with autoimmune hepatitis by treatment with sympathomimetic amines
- Author
-
Check Jh and Weidner J
- Subjects
myalgia ,business.industry ,Obstetrics and Gynecology ,Chronic fatigue ,Autoimmune hepatitis ,medicine.disease ,digestive system diseases ,Sympathomimetic amine ,Reproductive Medicine ,Sympathomimetic Amines ,immune system diseases ,Edema ,Immunology ,medicine ,medicine.symptom ,Dextroamphetamine Sulfate ,business - Abstract
PURPOSE To evaluate the effect of sympathomimetic amine therapy for a life threatening autoimmune disorder. MATERIALS AND METHODS Dextroamphetamine sulfate was used to treat edema, myalgia, and chronic fatigue associated with autoimmune hepatitis (AIH). RESULTS Sympathomimetic amine therapy completely abrogated the symptoms associated with AIH. CONCLUSIONS AIH should be added to the long list of chronic treatment-refractory conditions that respond quickly and effectively to treatment with sympathomimetic amines.
- Published
- 2014
6. Effect of an abnormal sperm chromatin structural assay (SCSA) on pregnancy outcome following (IVF) with ICSI in previous IVF failures
- Author
-
J. Krotec, V. Graziano, Matthew L. Check, Check Jh, and R. Cohen
- Subjects
Male ,medicine.medical_specialty ,Protein Conformation ,Fertilization in Vitro ,Abortion ,Biology ,Miscarriage ,Endocrinology ,Pregnancy ,Ongoing pregnancy ,medicine ,Humans ,Sperm Injections, Intracytoplasmic ,reproductive and urinary physiology ,Gynecology ,urogenital system ,Obstetrics ,Pregnancy Outcome ,medicine.disease ,Successful pregnancy ,Sperm ,Spermatozoa ,Chromatin ,Female ,Abnormal sperm - Abstract
A high DNA fragmentation index (DFI) when performing the sperm chromatin structural (SCSAr) assay was claimed to be so specific for male subfertility that even IVF with ICSI did not result in live pregnancies. The present study was designed to corroborate or refute these findings. The SCSA test was performed on the male partner from couples failing to have a successful pregnancy despite at least 2 previous IVF attempts. In contrast to the aforementioned studies, ongoing pregnancies were found despite working with a group of recalcitrant patients. Nevertheless, a high DFI score was associated with a trend for lower ongoing pregnancy rates especially related to a high miscarriage rate. Other more recent studies seem to support our conclusions. A high DFI score should influence a patient to choose IVF as a therapeutic modality sooner, especially with ICSI.
- Published
- 2005
7. Do antisperm antibodies cause functional impairment of the sperm membrane as manifested by a low hypoosmotic swelling test score?
- Author
-
Bollendorf A, Check Jh, and Jairaj S
- Subjects
Male ,medicine.medical_specialty ,Pregnancy ,Functional impairment ,biology ,Sperm membrane ,Cell Membrane ,Semen ,medicine.disease ,Sperm ,Spermatozoa ,Hypoosmotic swelling ,Endocrinology ,Osmotic Pressure ,Test score ,Internal medicine ,medicine ,biology.protein ,Humans ,Antibody ,Autoantibodies - Abstract
Low hypoosmotic swelling (HOS) test scores were found to be associated with lower pregnancy rates. The mechanism seems to be related not so much to impaired fertilization but to inhibition of implantation. The defect may be present in males with normal or subnormal semen specimens. However, anecdotal experience suggested that the subset of males with antisperm antibodies (ASAs) have a higher frequency of low HOS scores. The possibility exists that ASAs may impair the functional integrity of the sperm membrane. The study presented herein, artificially added ASAs to sperm to see if this could lower the HOS score. The study would also determine if chymotrypsin, a protein digestive enzyme, could improve HOS scores, if, in fact, they were lowered by the addition of ASAs. The results did not show a reduction in the HOS scores following the addition of ASAs. Thus, it would appear that there is no cause and effect with the simultaneous presence of low HOS scores and ASAs. Possibly, however, longer exposure or a higher concentration of antibodies is needed to lower HOS scores.
- Published
- 2000
8. Separation of sperm through a 12-layer percoll column decreases the percentage of sperm staining with quinacrine
- Author
-
K. McMonagle, Bollendorf A, R. Long, Check Jh, W. Hourani, and Matthew L. Check
- Subjects
Male ,X Chromosome ,Quinacrine Mustard ,Sexing ,Cell Separation ,Biology ,Y chromosome ,Andrology ,Endocrinology ,Y Chromosome ,Centrifugation, Density Gradient ,Humans ,Sex Preselection ,In Situ Hybridization, Fluorescence ,Fluorescent Dyes ,Sperm Count ,Staining and Labeling ,urogenital system ,Germinal cell ,Povidone ,Anatomy ,Silicon Dioxide ,Sperm ,Spermatozoa ,Staining ,%22">Fish ,Separation method ,Percoll - Abstract
Previous methods of enriching sperm with a higher percentage of Y-bearing sperm have been questioned because the claims that Y enrichment was present were based on quinacrine staining of the Y chromosome, and the enrichment was not confirmed by polymerase chain reaction (PCR) or fluorescent in situ hybridization (FISH) techniques. A technique was evaluated that theoretically could increase the percentage of X-bearing sperm by isolating a fraction of the "heaviest" sperm by passing them through 12 layers of discontinuous Percoll gradient. Initially 12 specimens were checked both before and then after separation with 12 layers of Percoll for percentage of Y sperm. The median for baseline Y percentage was 49% and after processing the percentage of Y dropped to 10%. An additional 19 specimens were checked after separation only. The median was 19%. The sample with the lowest preseparation % of quinacrine staining sperm was 45% and the highest was 54%. After 12-layer Percoll, the lowest percentage was 3% and the highest was 24%. There have been claims that quinacrine staining can falsely increase apparent Y-bearing sperm enrichment following certain separation procedures, e.g.. albumin separation, by nonspecific staining of autosomal chromosomes. If anything, then, it should falsely decrease X-bearing sperm enrichment. Thus, 12-layer Percoll separation may actually enrich for X-bearing sperm or possibly this procedure somehow nonspecifically inhibits the ability of quinacrine to stain the Y chromosome.
- Published
- 2000
9. Adverse Effect of Clomiphene Citrate on Sperm Morphology
- Author
-
Check Jh, B. Shanis, and A. Bollendorf
- Subjects
Male ,Infertility ,medicine.diagnostic_test ,medicine.medical_treatment ,Physiology ,Semen ,Semen analysis ,Biology ,medicine.disease ,Spermatozoa ,Sperm ,Clomiphene ,Male infertility ,Andrology ,Endocrinology ,Clomifene ,medicine ,Humans ,Ovulation induction ,Adverse effect ,Infertility, Male ,medicine.drug - Abstract
The beneficial effect of clomiphene citrate (CC) in treating male infertility is controversial. To evaluate the effects of CC on sperm morphology using strict criteria, the semen analyses of 74 men were evaluated at intervals ranging from 1 to 18 months of treatment. Seventy patients receiving no medication were used as control. The patients in each category were divided into three subgroups: A (1-3 months), B (4-6 months), and C (greater than 6 months). In the control group, there were no significant differences in percentages or total normal forms between baseline and repeat semen analysis at any interval. Treatment with CC for 1-3 months did not adversely affect percentages of normal forms. Treatment for greater than 3 months caused a highly significant decrease in percentage of normal forms. Three months of CC caused no change in the absolute number of morphologically normal sperm, but longer periods (greater than 6 months) were associated with a significant decrease. There was significant deterioration of sperm function as measured by percentage of normal forms in patients treated with CC for 4-18 months. The physiological clinical significance remains to be investigated.
- Published
- 1991
10. Correspondence
- Author
-
Check Jh
- Subjects
Text mining ,Reproductive Medicine ,business.industry ,Computer science ,Obstetrics and Gynecology ,Data mining ,business ,computer.software_genre ,computer ,Power (physics) - Published
- 1998
11. Interpretation and Misinterpretation of Semen Parameters
- Author
-
B S Shanis, A. Bollendorf, and Check Jh
- Subjects
Male ,Infertility ,Time Factors ,Sperm membrane ,media_common.quotation_subject ,Sample (material) ,Semen ,Fertility ,Biology ,Semen analysis ,Specimen Handling ,Andrology ,Endocrinology ,Pregnancy ,medicine ,Humans ,Diagnosis, Computer-Assisted ,Infertility, Male ,Sexual Abstinence ,media_common ,Sperm-Ovum Interactions ,Sperm Count ,medicine.diagnostic_test ,urogenital system ,medicine.disease ,Spermatozoa ,Sperm ,Male fertility ,Sperm Motility ,Female - Abstract
Semen analysis, which is traditionally used to evaluate male fertility, may be misleading if sample is lost or inadequately mixed. A short or excessive abstinence period may cause a low count or a high count with low motility. Damage from low temperature or delay in evaluation may decrease the reported motility. Computer-assisted semen analysis has eliminated some of the variability and has allowed the evaluation of other sperm motion variables such as sperm velocity, linearity, maximum and mean amplitude lateral head displacement, and beat-cross frequency. These measurements may also occasionally be misleading. Other tests may give a better indication of the function of sperm. The hamster egg penetration test has been used but is technically difficult, and perhaps that is why there is controversy as to the clinical value of the test in predicting subfertile sperm despite normal conventional semen analysis. Some recent data suggest that the hypo-osmotic swelling test, which determines the functional integrity of the sperm membrane, may be the appropriate prognosticator. There is a need for further studies to define the best method to determine whether a male factor is responsible for a couple's infertility.
- Published
- 1989
12. Case Report: Cystic Gynecomastia in a Male Treated with Clomiphene Citrate
- Author
-
Check Jh, Mortimer B. Hermel, Morton G. Murdock, and Jose F. Caro
- Subjects
Adult ,Male ,Gynecology ,medicine.medical_specialty ,Cysts ,business.industry ,Obstetrics and Gynecology ,medicine.disease ,Clomiphene ,Breast Diseases ,Reproductive Medicine ,Gynecomastia ,medicine ,Humans ,business - Published
- 1978
13. The risk of fetal anomalies as a result of progesterone therapy during pregnancy
- Author
-
Margaret Teichman, Amy Rankin, and Check Jh
- Subjects
Risk ,medicine.medical_specialty ,Abortion ,Injections, Intramuscular ,Pharmacotherapy ,Pregnancy ,Surveys and Questionnaires ,Hydroxyprogesterones ,medicine ,Humans ,Progesterone ,Retrospective Studies ,Gynecology ,Fetus ,Obstetrics ,business.industry ,17-alpha-Hydroxyprogesterone ,Suppositories ,Incidence (epidemiology) ,Infant, Newborn ,Abnormalities, Drug-Induced ,Obstetrics and Gynecology ,Retrospective cohort study ,medicine.disease ,Abortion, Spontaneous ,Pregnancy Trimester, First ,medicine.anatomical_structure ,Reproductive Medicine ,Vagina ,Gestation ,Drug Therapy, Combination ,Female ,business - Abstract
The incidence of congenital anomalies in infants born to 382 women treated with P was noted. Only five anomalies occurred in the infants born to women who had taken P. This study supports the data of Rock et al. by demonstrating a similar low incidence of birth defects in a much larger series of patients who also took a much higher dosage of P. Similarly, because only 1 of 189 patients treated with both P and 17-OHP developed anomalies, the data supports the study by Katz et al., suggesting no increase in anomalies related to 17-OHP therapy.
- Published
- 1986
14. Improved Fertility in Oligospermic Males Treated with Clomiphene Citrate
- Author
-
Check Jh and A.E. Rakoff
- Subjects
Male ,Infertility ,medicine.medical_specialty ,medicine.drug_class ,media_common.quotation_subject ,Population ,Physiology ,Fertility ,Clomiphene ,Health services ,Pregnancy ,Internal medicine ,medicine ,Humans ,education ,Infertility, Male ,media_common ,Base line ,education.field_of_study ,business.industry ,Obstetrics and Gynecology ,Oligospermia ,medicine.disease ,Clinical research ,Endocrinology ,Reproductive Medicine ,Female ,Gonadotropin ,business - Abstract
Significant improvements in oligospermia and asthenospermia can be achieved in men without elevation of base line gonadotropin levels or evidence of anatomical abnormalities by treatment with repeated cycles of clomiphene citrate, 25mg daily for 25 days, with 5 days' rest.
- Published
- 1977
15. The effect of leuprolide acetate in aiding induction of ovulation in hypergonadotropic hypogonadism: a case report
- Author
-
Chung H. Wu, Matthew L. Check, and Check Jh
- Subjects
Adult ,Ovulation ,endocrine system ,medicine.medical_specialty ,Menotropins ,medicine.drug_class ,media_common.quotation_subject ,Gonadotropin-Releasing Hormone ,Hypergonadotropic hypogonadism ,Internal medicine ,medicine ,Humans ,Receptor ,media_common ,Pregnancy ,biology ,business.industry ,Hypogonadism ,Obstetrics and Gynecology ,medicine.disease ,Endocrinology ,Reproductive Medicine ,Estrogen ,HMG-CoA reductase ,biology.protein ,Amenorrhea ,Female ,medicine.symptom ,Gonadotropin ,Leuprolide ,business ,hormones, hormone substitutes, and hormone antagonists - Abstract
A 43-year-old woman with a history of 5 years of amenorrhea sought help in achieving a pregnancy. Her gonadotropins were found to be elevated and thus she was diagnosed as having ovarian failure. She was made to ovulate on many occasions by suppressing her gonadotropins first with estrogen, then stimulating her ovaries with hMG. However, she became refractory to this therapy and she was switched from estrogen to LA to suppress gonadotropins. The woman ovulated three times just with leuprolide therapy before any hMG was added. A possible hypothesis is that, on the way down to subnormal levels of LH and FSH, a critical level of gonadotropins was attained where they were still high enough to stimulate the follicles, but low enough to allow restoration of gonadotropin receptors, which previously had been down-regulated by the elevated gonadotropin levels.
- Published
- 1988
16. Severe ovarian hyperstimulation syndrome from treatment with urinary follicle-stimulating hormone: two cases
- Author
-
Chung-Hsiu Wu, Harriet G. Adelson, Check Jh, and Ben Gocial
- Subjects
Gynecology ,Adult ,medicine.medical_specialty ,Chemotherapy ,Menotropins ,medicine.drug_class ,business.industry ,Urinary system ,medicine.medical_treatment ,Obstetrics and Gynecology ,Ovarian hyperstimulation syndrome ,medicine.disease ,Anovulation ,Follicle-stimulating hormone ,Endocrinology ,Reproductive Medicine ,Ovulation Induction ,Internal medicine ,medicine ,Humans ,Female ,Gonadotropin ,Follicle Stimulating Hormone ,business ,Polycystic Ovary Syndrome - Abstract
Deux cas cliniques d'hyperstimulation ovarienne severe sont rapportes apres utilisation de doses relativement faibles de FSH pure chez des patientes qui ont ulterieurement concu avec un traitement classique par HMG. L'avantage theorique des FSH pures sur l'HMG dans la prevention des syndromes d'hyperstimulation doit donc etre reconsidere. Le role joue par l'injection d'HCG pour declencher l'ovulation doit etre pris en compte chez ces patientes traitees par FSH pure
- Published
- 1985
17. The hypoosmotic swelling test as a useful adjunct to the semen analysis to predict fertility potential
- Author
-
B S Shanis, Chung H. Wu, Nowroozi K, Check Jh, Richard H. Epstein, and A. Bollendorf
- Subjects
Infertility ,Male ,medicine.medical_specialty ,Osmosis ,media_common.quotation_subject ,Semen ,Fertility ,Semen analysis ,Predictive Value of Tests ,Pregnancy ,medicine ,Humans ,media_common ,Retrospective Studies ,Gynecology ,medicine.diagnostic_test ,business.industry ,Obstetrics and Gynecology ,medicine.disease ,Sperm ,Spermatozoa ,Test (assessment) ,Reproductive Medicine ,Predictive value of tests ,Female ,business - Abstract
The sperm HOS test was highly predictive of eventual achievement of pregnancy in women in whom other infertility factors had been corrected. No woman conceived whose partner's HOS was less than 50%. The results of spermiograms did not correlate with conception rate.
- Published
- 1989
18. Ovulation induction and pregnancy with an estrogen-gonadotropin stimulation technique in a menopausal woman with marked hypoplastic ovaries
- Author
-
Jeffrey S. Chase, Harriet G. Adelson, Chung H. Wu, and Check Jh
- Subjects
Adult ,endocrine system ,medicine.medical_specialty ,Menotropins ,medicine.drug_class ,media_common.quotation_subject ,medicine.medical_treatment ,Menopause, Premature ,Ethinyl Estradiol ,Gonadotropin stimulation ,Ovulation Induction ,Pregnancy ,Internal medicine ,medicine ,Elevated gonadotropins ,Humans ,Receptor ,Ovulation ,media_common ,business.industry ,Ovary ,Obstetrics and Gynecology ,medicine.disease ,Endocrinology ,Estrogen ,Ovulation induction ,Female ,Menopause ,business ,hormones, hormone substitutes, and hormone antagonists - Abstract
Summary A case is described of a woman with ovarian failure and documented atrophic ovaries in whom ovulation was achieved with the use of high-dose estrogen and human menopausal gonadotropins. The proposed mechanism involves a reduction in the elevated gonadotropins, which restored an adequate number of receptors. Thus sensitivity to exogenous menotropins was reestablished. (Am J Obstet Gynecol 1989;160:405-6.)
- Published
- 1989
19. Improved semen quality after a short-interval second ejaculation
- Author
-
Jeffrey S. Chase and Check Jh
- Subjects
Gynecology ,Adult ,Male ,medicine.medical_specialty ,Time Factors ,Sperm Count ,business.industry ,Ejaculation ,Obstetrics and Gynecology ,Semen ,Oligospermia ,medicine.disease ,Short interval ,Semen quality ,Reproductive Medicine ,Pregnancy ,medicine ,Humans ,Female ,business - Abstract
Les auteurs montrent que chez les oligospermiques plus que chez les sujets normaux, une 2eme ejaculation 30 a 60 minutes apres la 1ere fournit un specimen plus riche en spermatozoides. Ceci peut etre le fait de la reduction du volume seminal. Il semble que ceux qui ameliorent leur score dans le 2e ejaculat obtiennent des grossesses plus facilement
- Published
- 1985
20. First-trimester serum levels of the beta-subunit of human chorionic gonadotropin in a tubal molar pregnancy
- Author
-
Chung H. Wu, Nowroozi K, Check Jh, and Jeffrey S. Chase
- Subjects
Adult ,endocrine system ,medicine.medical_specialty ,animal structures ,Chorionic Gonadotropin ,Human chorionic gonadotropin ,Andrology ,Molar pregnancy ,Pregnancy ,β subunit ,medicine ,Humans ,Chorionic Gonadotropin, beta Subunit, Human ,Uterine Neoplasm ,reproductive and urinary physiology ,urogenital system ,business.industry ,Obstetrics ,Obstetrics and Gynecology ,Hydatidiform Mole ,medicine.disease ,female genital diseases and pregnancy complications ,Peptide Fragments ,First trimester ,Pregnancy Trimester, First ,Uterine Neoplasms ,Female ,Pregnancy, Tubal ,business - Abstract
A woman is described in whom the levels of the beta-subunit of human chorionic gonadotropin were rising in a pattern consistent with a tubal pregnancy. A tubal molar pregnancy was found. Thus an early ectopic molar pregnancy is not distinguishable from a nontrophoblastic tubal pregnancy on the basis of human chorionic gonadotropin levels.
- Published
- 1987
21. Correlation of semen analysis and hypoosmotic swelling test with subsequent pregnancies
- Author
-
A. Bollendorf, Check Jh, Nowroozi K, and Chung H. Wu
- Subjects
Infertility ,Male ,Sperm-Ovum Interactions ,Pregnancy ,Osmosis ,medicine.diagnostic_test ,business.industry ,media_common.quotation_subject ,Semen ,Fertility ,Semen analysis ,medicine.disease ,Test (assessment) ,Correlation ,Andrology ,Endocrinology ,medicine ,Gestation ,Humans ,Female ,business ,media_common - Abstract
The hypoosmotic swelling (HOS) test was evaluated in 40 men whose wives had no apparent fertility factors. Only one of 29 men with normal semen parameters had a surbnormal HOS test, and that couple failed to conceive compared to 27 of 28 with normal HOS test who did conceive. All five couples with husbands with subnormal semen parameters but with normal HOS tests achieved a pregnancy, but none of the three with abnormal HOS tests achieved a pregnancy. The results suggest that the HOS test might be of value in predicting which couples should be more patient despite low semen parameters.
- Published
- 1988
22. Evaluating glass, polystyrene, and polypropylene containers for semen collection and sperm washing
- Author
-
A. Bollendorf, B S Shanis, Check Jh, and Chung H. Wu
- Subjects
Male ,medicine.medical_specialty ,Materials science ,medicine.medical_treatment ,Semen ,Semen analysis ,Polypropylenes ,Semen collection ,Specimen Handling ,chemistry.chemical_compound ,Endocrinology ,medicine ,Humans ,Polypropylene ,Chromatography ,medicine.diagnostic_test ,Artificial insemination ,Sperm washing ,Sperm ,Spermatozoa ,Surgery ,chemistry ,Polystyrenes ,Polystyrene ,Glass ,Plastics - Abstract
The effects of glass, polystyrene, and polypropylene containers on semen parameters as measured by Cell Soft computer-assisted semen analysis and hypoosmotic swelling (HOS) tests were assessed in unwashed specimens and again after sperm washing and swim-up procedures. A superiority in unwashed specimens was observed in glass versus polystyrene concerning velocity, motility percentage, and HOS testing (p less than 0.01). Also, superiority of glass versus polystyrene was demonstrated for linearity and ALH (p less than 0.05). Glass was only superior to polypropylene in categories of motility and HOS testing (p less than 0.05 and p less than 0.01, respectively). There was no category in which plastic was statistically superior to glass in the unwashed specimens. Concerning washed and swim-up specimens, there were no semen parameters in which there was any superiority demonstrated of either glass or plastic. Unless some future proof that the differences in semen parameters demonstrated in this study have no clinical significance, these data suggest that the collection of semen samples for sperm analysis or therapeutic use should be performed in glass containers.
- Published
- 1988
23. Anosmia and hypogonadism associated with elevated luteinizing hormone levels and multiple congenital anomalies
- Author
-
Alvin F. Goldfarb, Check Jh, Philip Slipyan, and A.E. Rakoff
- Subjects
Adult ,medicine.medical_specialty ,business.industry ,Hypogonadism ,Anosmia ,Obstetrics and Gynecology ,Luteinizing Hormone ,Olfaction Disorders ,Endocrinology ,Internal medicine ,medicine ,Humans ,Amenorrhea ,Abnormalities, Multiple ,Female ,medicine.symptom ,Luteinizing hormone ,business - Published
- 1977
24. Ovulation induction in hypergonadotropic amenorrhea with estrogen and human menopausal gonadotropin therapy
- Author
-
Check Jh and Jeffrey S. Chase
- Subjects
Adult ,medicine.medical_specialty ,Menotropins ,medicine.drug_class ,medicine.medical_treatment ,media_common.quotation_subject ,Follicle-stimulating hormone ,Ovulation Induction ,Internal medicine ,medicine ,Humans ,Ovulation ,Amenorrhea ,media_common ,Gynecology ,Estrogens, Conjugated (USP) ,business.industry ,Female infertility ,Obstetrics and Gynecology ,Estrogens ,Luteinizing Hormone ,medicine.disease ,Endocrinology ,Reproductive Medicine ,Ovulation induction ,Female ,medicine.symptom ,Gonadotropin ,Follicle Stimulating Hormone ,Luteinizing hormone ,business ,Infertility, Female - Abstract
Les auteurs rapportent la possibilite d'obtenir des femmes jeunes presentant un tableau de menopause precoce, une stimulation d'ovulation voir meme d'une grossesse dans 2 cas sur 5. La stimulation ovarienne avec la sequence HMG-HCG n'est cependant possible qu'apres une impregnation prealable par des estrogenes. Ceci pourrait indiquer qu'en presence de taux eleves de FSH, il existe une regulation negative du recepteur de FSH qui empeche l'efficacite de la stimulation par HMG
- Published
- 1984
25. Virilizing congenital adrenal hyperplasia with normal dehydroepiandrosterone sulfate
- Author
-
Check Jh and Joseph W. Krotec
- Subjects
medicine.medical_specialty ,medicine.drug_class ,Dehydroepiandrosterone ,chemistry.chemical_compound ,Dehydroepiandrosterone sulfate ,Internal medicine ,Hydroxyprogesterones ,Medicine ,Humans ,Congenital adrenal hyperplasia ,Child ,Aldehyde-Lyases ,Adrenal Hyperplasia, Congenital ,business.industry ,Dehydroepiandrosterone Sulfate ,17-alpha-Hydroxyprogesterone ,Obstetrics and Gynecology ,Steroid 17-alpha-Hydroxylase ,Androgen ,medicine.disease ,Virilism ,Endocrinology ,chemistry ,Female ,business - Published
- 1983
26. Androgen therapy of a varicocele
- Author
-
A.E. Rakoff and Check Jh
- Subjects
Gynecology ,Infertility ,Adult ,Male ,medicine.medical_specialty ,Pregnancy ,business.industry ,Urology ,Varicocele ,Fluoxymesterone ,medicine.disease ,Androgen Therapy ,medicine ,Semen volume ,Humans ,Female ,business ,After treatment ,Infertility, Male ,medicine.drug - Abstract
A case of asthenospermia and decreased semen volume with consequent infertility is reported. The patient had large bilateral varicoceles but refused an operation. Significant improvement of volume and motility occurred after treatment with fluoxymesterone and pregnancy was achieved.
- Published
- 1977
27. Male Sex Preselection: Swim-Up Technique and Insemination of Women After Ovulation Induction
- Author
-
B S Shanis, S O Cooper, Check Jh, and A. Bollendorf
- Subjects
Male ,Infertility ,Menotropins ,Offspring ,media_common.quotation_subject ,medicine.medical_treatment ,Physiology ,Semen ,Biology ,Insemination ,Clomiphene ,Specimen Handling ,Andrology ,Endocrinology ,Ovulation Induction ,medicine ,Humans ,Sex Preselection ,Ovulation ,Insemination, Artificial ,media_common ,Artificial insemination ,medicine.disease ,Spermatozoa ,Female ,Ovulation induction ,Genetic Engineering ,Infertility, Female - Abstract
Insemination of women with sperm treated by the swim-up technique resulted in 81% male offspring. This was achieved even in women taking ovulation-inducing drugs, in whom the albumin gradient separation technique not only is not effective in male preselection but in which the female sex is favored. Confirmation of these initial data is needed as well as an investigation of the swim-up's efficacy of producing male offspring in women not taking ovulation-inducing drugs.
- Published
- 1989
28. False-positive human chorionic gonadotropin levels caused by a heterophile antibody with the immunoradiometric assay
- Author
-
Barry Elkins, Check Jh, Chung H. Wu, Caroline Lauer, Nowroozi K, and Jeffrey S. Chase
- Subjects
endocrine system ,Immunoradiometric assay ,business.industry ,Radioimmunoassay ,Antibodies, Monoclonal ,nutritional and metabolic diseases ,Obstetrics and Gynecology ,Antibodies, Heterophile ,Cross Reactions ,Middle Aged ,Chorionic Gonadotropin ,Peptide Fragments ,Human chorionic gonadotropin ,Heterophile antibody ,Pregnancy ,Immunology ,Humans ,Medicine ,Chorionic Gonadotropin, beta Subunit, Human ,False Positive Reactions ,Female ,business - Abstract
A case of a false-positive test for the β-subunit of human chorionic gonadotropin as performed by the immunoradiometric assay is described. Further studies revealed that this problem was secondary to a cross-reacting heterophile antibody.
- Published
- 1988
29. Ovarian pregnancy with a contralateral corpus luteum: Case report
- Author
-
Jeffrey S. Chase and Check Jh
- Subjects
Adult ,endocrine system ,medicine.medical_specialty ,medicine.medical_treatment ,Right ovary ,Ovary ,Corpus Luteum ,Pregnancy ,Laparotomy ,medicine ,Humans ,Ovarian pregnancy ,Ultrasonography ,business.industry ,Obstetrics ,Obstetrics and Gynecology ,medicine.disease ,Pregnancy, Ectopic ,medicine.anatomical_structure ,Female ,business ,Corpus luteum - Abstract
A case is described of a woman who was found to have an ovarian pregnancy on the left with a corpus luteum on the right ovary. This was determined by both pelvic sonography and laparotomy. The case did fulfill the four criteria of Spiegelberg.
- Published
- 1986
30. CD-Rom. Item 12. Survival and pregnancy rates of pronuclear stage human embryos cryopreserved and thawed using a single step addition and removal of cryoprotectant.
- Author
-
Baker, AF, Check, JH, and Hourani, CL
- Published
- 1996
- Full Text
- View/download PDF
31. Standards in semen examination: publishing reproducible and reliable data based on high-quality methodology
- Author
-
Lars Björndahl, Christopher L R Barratt, David Mortimer, Ashok Agarwal, Robert J Aitken, Juan G Alvarez, Natalie Aneck-Hahn, Stefan Arver, Elisabetta Baldi, Lluís Bassas, Florence Boitrelle, Riana Bornman, Douglas T Carrell, José A Castilla, Gerardo Cerezo Parra, Jerome H Check, Patricia S Cuasnicu, Sally Perreault Darney, Christiaan de Jager, Christopher J De Jonge, Joël R Drevet, Erma Z Drobnis, Stefan S Du Plessis, Michael L Eisenberg, Sandro C Esteves, Evangelini A Evgeni, Alberto Ferlin, Nicolas Garrido, Aleksander Giwercman, Ilse G F Goovaerts, Trine B Haugen, Ralf Henkel, Lars Henningsohn, Marie-Claude Hofmann, James M Hotaling, Piotr Jedrzejczak, Pierre Jouannet, Niels Jørgensen, Jackson C Kirkman Brown, Csilla Krausz, Maciej Kurpisz, Ulrik Kvist, Dolores J Lamb, Hagai Levine, Kate L Loveland, Robert I McLachlan, Ali Mahran, Liana Maree, Sarah Martins da Silva, Michael T Mbizvo, Andreas Meinhardt, Roelof Menkveld, Sharon T Mortimer, Sergey Moskovtsev, Charles H Muller, Maria José Munuce, Monica Muratori, Craig Niederberger, Cristian O’Flaherty, Rafael Oliva, Willem Ombelet, Allan A Pacey, Michael A Palladino, Ranjith Ramasamy, Liliana Ramos, Nathalie Rives, Eduardo Rs Roldan, Susan Rothmann, Denny Sakkas, Andrea Salonia, Maria Cristina Sánchez-Pozo, Rosanna Sapiro, Stefan Schlatt, Peter N Schlegel, Hans-Christian Schuppe, Rupin Shah, Niels E Skakkebæk, Katja Teerds, Igor Toskin, Herman Tournaye, Paul J Turek, Gerhard van der Horst, Monica Vazquez-Levin, Christina Wang, Alex Wetzels, Theodosia Zeginiadou, Armand Zini, Faculty of Medicine and Pharmacy, Clinical sciences, Biology of the Testis, Centre for Reproductive Medicine - Gynaecology, Génétique, Reproduction et Développement (GReD), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Centre National de la Recherche Scientifique (CNRS), CHU Rouen, Normandie Université (NU), UNIROUEN - UFR Santé (UNIROUEN UFR Santé), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU), Neuroendocrine, Endocrine and Germinal Differentiation Communication (NorDic), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Björndahl, L, Barratt, Clr, Mortimer, D, Agarwal, A, Aitken, Rj, Alvarez, Jg, Aneck-Hahn, N, Arver, S, Baldi, E, Bassas, L, Boitrelle, F, Bornman, R, Carrell, Dt, Castilla, Ja, Cerezo Parra, G, Check, Jh, Cuasnicu, P, Darney, Sp, de Jager, C, De Jonge, Cj, Drevet, Jr, Drobnis, Ez, Du Plessis, S, Eisenberg, Ml, Esteves, Sc, Evgeni, Ea, Ferlin, A, Garrido, N, Giwercman, A, Goovaerts, Igf, Haugen, Tb, Henkel, R, Henningsohn, L, Hofmann, Mc, Hotaling, Jm, Jedrzejczak, P, Jouannet, P, Jørgensen, N, Kirkman Brown, Jc, Krausz, C, Kurpisz, M, Kvist, U, Lamb, Dj, Levine, H, Loveland, Kl, Mclachlan, Ri, Mahran, A, Maree, L, Martins da Silva, S, Mbizvo, Mt, Meinhardt, A, Menkveld, R, Mortimer, St, Moskovtsev, S, Muller, Ch, Munuce, Mj, Muratori, M, Niederberger, C, O'Flaherty, C, Oliva, R, Ombelet, W, Pacey, Aa, Palladino, Ma, Ramasamy, R, Ramos, L, Rives, N, Roldan, Er, Rothmann, S, Sakkas, D, Salonia, A, Sánchez-Pozo, Mc, Sapiro, R, Schlatt, S, Schlegel, Pn, Schuppe, Hc, Shah, R, Skakkebæk, Ne, Teerds, K, Toskin, I, Tournaye, H, Turek, Pj, van der Horst, G, Vazquez-Levin, M, Wang, C, Wetzels, A, Zeginiadou, T, Zini, A., Pacey, Allan/0000-0002-4387-8871, Arver, Stefan/0000-0002-2925-355X, Mortimer, David/0000-0002-0638-2893, Barratt, christopher/0000-0003-0062-9979, Kirkman-Brown, Jackson, C/0000-0003-2833-8970, Bjorndahl, Lars/0000-0002-4709-5807, Baldi, Elisabetta/0000-0003-1808-3097, Aitken, Robert John/0000-0002-9152-156X, Bjorndahl, Lars, Barratt, Christopher L. R., Mortimer, David, Agarwal, Ashok, Aitken, Robert J., Alvarez, Juan G., Aneck-Hahn, Natalie, Arver, Stefan, Baldi, Elisabetta, Bassas, Lluis, Boitrelle, Florence, Bornman, Riana, Carrell, Douglas T., Castilla, Jose A., Cerezo Parra, Gerardo, Check, Jerome H., Cuasnicu, Patricia S., Darney, Sally Perreault, de Jager, Christiaan, De Jonge, Christopher J., Drevet, Joel R., Drobnis, Erma Z., Du Plessis, Stefan S., Eisenberg, Michael L., Esteves, Sandro C., Evgeni, Evangelini A., Ferlin, Alberto, Garrido, Nicolas, Giwercman, Aleksander, Goovaerts, Ilse G. F., Haugen, Trine B., Henkel, Ralf, Henningsohn, Lars, Hofmann, Marie-Claude, Hotaling, James M., Jedrzejczak, Piotr, Jouannet, Pierre, Jorgensen, Niels, Brown, Jackson C. Kirkman, Krausz, Csilla, Kurpisz, Maciej, Kvist, Ulrik, Lamb, Dolores J., Levine, Hagai, Loveland, Kate L., McLachlan, Robert, I, Mahran, Ali, Maree, Liana, da Silva, Sarah Martins, Mbizvo, Michael T., Meinhardt, Andreas, Menkveld, Roelof, Mortimer, Sharon T., Moskovtsev, Sergey, Muller, Charles H., Jose Munuce, Maria, Muratori, Monica, Niederberger, Craig, O'Flaherty, Cristian, Oliva, Rafael, OMBELET, Willem, Pacey, Allan A., Palladino, Michael A., Ramasamy, Ranjith, Ramos, Liliana, Rives, Nathalie, Roldan, Eduardo Rs, Rothmann, Susan, Sakkas, Denny, Salonia, Andrea, Cristina Sanchez-Pozo, Maria, Sapiro, Rosanna, Schlatt, Stefan, Schlegel, Peter N., Schuppe, Hans-Christian, Shah, Rupin, Skakkebaek, Niels E., Teerds, Katja, Toskin, Igor, Tournaye, Herman, Turek, Paul J., van der Horst, Gerhard, Vazquez-Levin, Monica, Wang, Christina, Wetzels, Alex, Zeginiadou, Theodosia, and Zini, Armand
- Subjects
Reproducitibility ,[SDV]Life Sciences [q-bio] ,andrology ,basic semen examination ,journal requirements ,laboratory training ,patient security ,quality control ,reproducibility ,reproductive medicine ,science development ,standardized laboratory procedures ,Humans ,Reproducibility of Results ,Publishing ,Semen ,Semen Analysis ,Andrology ,Obstetrics & Reproductive Medicine ,Biology ,11 Medical and Health Sciences ,Reproductive Biology ,Science & Technology ,Rehabilitation ,Obstetrics & Gynecology ,Obstetrics and Gynecology ,Reproductive Medicine ,16 Studies in Human Society ,Human and Animal Physiology ,Fysiologie van Mens en Dier ,Human medicine ,Life Sciences & Biomedicine - Abstract
Biomedical science is rapidly developing in terms of more transparency, openness and reproducibility of scientific publications. This is even more important for all studies that are based on results from basic semen examination. Recently two concordant documents have been published: the 6th edition of the WHO Laboratory Manual for the Examination and Processing of Human Semen, and the International Standard ISO 23162:2021. With these tools, we propose that authors should be instructed to follow these laboratory methods in order to publish studies in peer-reviewed journals, preferable by using a checklist as suggested in an Appendix to this article.
- Published
- 2022
32. Significant Palliative Benefits Following Therapy With Mifepristone for Advanced Treatment Resistant Small Cell Lung Cancer.
- Author
-
Check JH, Check DL, DO TP, Srivastava M, and Check E
- Subjects
- Male, Humans, Middle Aged, Mifepristone therapeutic use, Mifepristone pharmacology, Receptors, Progesterone, Progesterone pharmacology, Lung Neoplasms drug therapy, Small Cell Lung Carcinoma drug therapy, Carcinoma, Non-Small-Cell Lung drug therapy
- Abstract
Background/aim: Progesterone receptor antagonists have been found to provide significant extension of life and considerable palliative benefits in a large variety of very advanced cancers. Most of these treated cancers lack the classical nuclear progesterone receptor (nPR). The hypothesized targets are membrane (m) PRs to inhibit progesterone induced blocking factor (PIBF). To date, there have been no case reports documenting the efficacy of PR antagonists for small cell lung cancer (SCLC) confirmed by pathological analysis. The case reported here demonstrates the efficacy of the single oral agent mifepristone in treating resistant SCLC., Case Report: A 58-year-old man, presenting with a persistent cough, dyspnea on exertion, and marked weakness, was diagnosed with stage IV non-SCLC (NSCLC) that tested positive for the EGFR mutation. He was treated with the single agent osimertinib. When symptoms returned eight months later, along with radiographic evidence of marked cancer progression, a lung biopsy showed SCLC. He failed to respond to pembrolizumab and subsequently to atezolizumab. He was then treated with the single agent mifepristone 200 mg per day orally. He showed marked clinical improvement associated with marked radiographic improvement. Though clinically doing very well, after one year, his dominant lesion increased in size. His oncologist elected to stop mifepristone and treat with camrelizumab with anlototinib. His clinical condition deteriorated on these drugs, and he died five months later., Conclusion: SCLC can be added to the long list of very advanced cancers that are treatment resistant to standard therapy, but respond well to PR antagonists., (Copyright © 2024 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
33. Lung Cancer - Standard Therapy and the Use of a Novel, Highly Effective, Well Tolerated, Treatment With Progesterone Receptor Modulators.
- Author
-
Check JH, Poretta T, Check D, and Srivastava M
- Subjects
- Animals, Humans, Mice, Immunotherapy, Progesterone, Steroids, Treatment Outcome, Lung Neoplasms drug therapy, Lung Neoplasms genetics, Receptors, Progesterone antagonists & inhibitors
- Abstract
The most recent successful advances in lung cancer therapy have directly and increasingly focused on personalized tumor genetic/epigenetic/immunologic profiling, and the identification and development of novel pharmacologic agents aimed at those mutations [e.g., epidermal growth factor receptor (EGFR), Kristen rat sarcoma viral oncogene homolog (KRAS), anaplastic lymphoma kinase (ALK) and immunotherapy against programmed cell death protein 1 (PD-1) and its ligands] which have extended life and provided palliation for lung cancer-patients positive for these mutations. The objective of this study is to provide a review of the large number of drugs and their efficacy as of 2022, for lung cancer, but also introduce a novel treatment that has the potential, based on one controlled murine lung cancer study and 5 anecdotal human cases, that showed marked palliative and longevity benefits in very advanced lung cancer with no other treatment options, i.e., progesterone receptor (PR) antagonists targeting the immunosuppressive protein, the progesterone induced blocking factor (PIBF). Credibility, however, will only be provided when the efficacy can be demonstrated in a large series of lung cancer cases ideally with certain controls. Thus, the ultimate objective of the review is to interest oncologists with a large population of lung cancer patients to perform a well powered study to corroborate or refute the limited experience to date with PR antagonist therapy., (Copyright © 2023 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
34. The role of progesterone and the progesterone receptor in cancer: progress in the last 5 years.
- Author
-
Check JH and Check DL
- Subjects
- Humans, Mifepristone pharmacology, Mifepristone therapeutic use, Receptors, Progesterone metabolism, Receptors, Progesterone therapeutic use, Neoplasms drug therapy, Progesterone therapeutic use
- Abstract
Introduction: Patients with various advanced cancers devoid of nuclear progesterone receptors (nPR) have demonstrated increased quality and length of life when treated with the PR modulator mifepristone, which likely works by interacting with membrane PRs (mPR)., Areas Covered: Two immunomodulatory proteins are discussed that seem to play a role in cancers that proliferate whether the malignant tumor is positive or negative for the nPR. These two proteins are the progesterone receptor membrane component-1 (PGRMC-1) and the progesterone-induced blocking factor (PIBF). Both PGRMC-1 and the parent form of PIBF foster increased tumor aggressiveness, whereas splice variants of the 90 kDa form of PIBF inhibit immune response against cancer cells., Expert Opinion: The marked clinical improvement following 200-300 mg of mifepristone is likely related to blocking PIBF. In the low dosage used, mifepristone likely acts as an agonist for PGRMC-1 protein. Mifepristone may be less effective for cancers positive for the nPR because the nPR may be protective and blocking it may have detrimental effects. Based on this hypothetical model, the development of other potential treatment options to provide even greater efficacy for treating cancer are discussed.
- Published
- 2023
- Full Text
- View/download PDF
35. Standards in semen examination: publishing reproducible and reliable data based on high-quality methodology.
- Author
-
Björndahl L, Barratt CLR, Mortimer D, Agarwal A, Aitken RJ, Alvarez JG, Aneck-Hahn N, Arver S, Baldi E, Bassas L, Boitrelle F, Bornman R, Carrell DT, Castilla JA, Cerezo Parra G, Check JH, Cuasnicu PS, Darney SP, de Jager C, De Jonge CJ, Drevet JR, Drobnis EZ, Du Plessis SS, Eisenberg ML, Esteves SC, Evgeni EA, Ferlin A, Garrido N, Giwercman A, Goovaerts IGF, Haugen TB, Henkel R, Henningsohn L, Hofmann MC, Hotaling JM, Jedrzejczak P, Jouannet P, Jørgensen N, Kirkman Brown JC, Krausz C, Kurpisz M, Kvist U, Lamb DJ, Levine H, Loveland KL, McLachlan RI, Mahran A, Maree L, Martins da Silva S, Mbizvo MT, Meinhardt A, Menkveld R, Mortimer ST, Moskovtsev S, Muller CH, Munuce MJ, Muratori M, Niederberger C, O'Flaherty C, Oliva R, Ombelet W, Pacey AA, Palladino MA, Ramasamy R, Ramos L, Rives N, Roldan ER, Rothmann S, Sakkas D, Salonia A, Sánchez-Pozo MC, Sapiro R, Schlatt S, Schlegel PN, Schuppe HC, Shah R, Skakkebæk NE, Teerds K, Toskin I, Tournaye H, Turek PJ, van der Horst G, Vazquez-Levin M, Wang C, Wetzels A, Zeginiadou T, and Zini A
- Subjects
- Humans, Reproducibility of Results, Peer Review, Publishing, Semen, Semen Analysis methods
- Abstract
Biomedical science is rapidly developing in terms of more transparency, openness and reproducibility of scientific publications. This is even more important for all studies that are based on results from basic semen examination. Recently two concordant documents have been published: the 6th edition of the WHO Laboratory Manual for the Examination and Processing of Human Semen, and the International Standard ISO 23162:2021. With these tools, we propose that authors should be instructed to follow these laboratory methods in order to publish studies in peer-reviewed journals, preferable by using a checklist as suggested in an Appendix to this article., (© The Author(s) 2022. Published by Oxford University Press on behalf of European Society of Human Reproduction and Embryology.)
- Published
- 2022
- Full Text
- View/download PDF
36. New Insights as to Why Progesterone Receptor Modulators, such as Mifepristone, Seem to Be More Effective in Treating Cancers that Are Devoid of the Classical Nuclear Progesterone Receptor.
- Author
-
Check JH and Check D
- Subjects
- Animals, Biomarkers, Tumor, Cell Proliferation drug effects, Clinical Studies as Topic, Disease Models, Animal, Disease Susceptibility, Drug Discovery, Drug Evaluation, Preclinical, Gene Expression Regulation, Neoplastic drug effects, Humans, Membrane Proteins genetics, Membrane Proteins metabolism, Molecular Targeted Therapy, Neoplasms etiology, Neoplasms metabolism, Neoplasms mortality, Prognosis, Receptors, Progesterone genetics, Receptors, Progesterone metabolism, Treatment Outcome, Antineoplastic Agents, Hormonal pharmacology, Antineoplastic Agents, Hormonal therapeutic use, Mifepristone pharmacology, Mifepristone therapeutic use, Neoplasms drug therapy, Receptors, Progesterone antagonists & inhibitors
- Abstract
Mifepristone treatment for advanced cancer has demonstrated considerable improvement in both length and quality of life in patients who no longer have any other treatment options. The target is the progesterone induced blocking factor (PIBF), which helps the tumor to invade the normal tissue and proliferate and suppress cellular immunity. Most of the benefit has been observed in cancers not associated with the classical nuclear progesterone receptor (nPR). There are data showing that the presence of a nPR may be associated with a better prognosis. Membrane PRs seem to be responsible for PIBF secretion. Mifepristone, possibly fails to block another P associated protein that enables the tumor to proliferate, e.g., the progesterone receptor membrane component-1 (PGRMC-1) protein. One hypothesis is that the nPR helps to inhibit tumor production of PGRMC-1 protein. Thus, mifepristone may inhibit tumor spread by suppressing PIBF, but this may be negated by blocking the nPR, allowing PGRMC-1 levels to increase., (Copyright © 2021 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
37. A Hypothetical Model Suggesting Some Possible Ways That the Progesterone Receptor May Be Involved in Cancer Proliferation.
- Author
-
Check JH and Check DL
- Subjects
- Cell Cycle drug effects, Cell Cycle genetics, Cell Line, Tumor, Cell Proliferation drug effects, Female, Fetus, Gene Expression Regulation, Humans, Immune Tolerance drug effects, Neoplasms drug therapy, Neoplasms immunology, Neoplasms pathology, Placenta drug effects, Placenta immunology, Pregnancy, Pregnancy Proteins antagonists & inhibitors, Pregnancy Proteins immunology, Receptors, Progesterone antagonists & inhibitors, Receptors, Progesterone immunology, Signal Transduction, Suppressor Factors, Immunologic antagonists & inhibitors, Suppressor Factors, Immunologic immunology, Tumor Microenvironment drug effects, Tumor Microenvironment genetics, Tumor Microenvironment immunology, Antineoplastic Agents, Hormonal therapeutic use, Hormone Antagonists therapeutic use, Mifepristone therapeutic use, Neoplasms genetics, Pregnancy Proteins genetics, Receptors, Progesterone genetics, Suppressor Factors, Immunologic genetics
- Abstract
Cancer and the fetal-placental semi-allograft share certain characteristics, e.g., rapid proliferation, the capacity to invade normal tissue, and, related to the presence of antigens foreign to the host, the need to evade immune surveillance. Many present-day methods to treat cancer use drugs that can block a key molecule that is important for one or more of these characteristics and thus reduce side effects. The ideal molecule would be one that is essential for both the survival of the fetus and malignant tumor, but not needed for normal cells. There is a potential suitable candidate, the progesterone induced blocking factor (PIBF). The parent 90 kilodalton (kDa) form seems to be required for cell-cycle regulation, required by both the fetal-placental unit and malignant tumors. The parent form may be converted to splice variants that help both the fetus and tumors escape immune surveillance, especially in the fetal and tumor microenvironment. Evidence suggests that membrane progesterone receptors are involved in PIBF production, and indeed there has been anecdotal evidence that progesterone receptor antagonists, e.g., mifepristone, can significantly improve longevity and quality of life, with few side effects.
- Published
- 2021
- Full Text
- View/download PDF
38. Palliative Benefits of Oral Mifepristone for the Treatment of Metastatic Fibroblastic Osteosarcoma.
- Author
-
Check JH, Check D, Poretta T, and Wilson C
- Subjects
- Administration, Oral, Bone Neoplasms pathology, Cancer Pain drug therapy, Humans, Male, Middle Aged, Neoplasm Metastasis, Osteosarcoma pathology, Quality of Life, Tibia, Treatment Outcome, Bone Neoplasms drug therapy, Mifepristone administration & dosage, Osteosarcoma drug therapy, Palliative Care methods
- Abstract
Background/aim: It has been hypothesized that many, or even most cancers, utilize a unique immunomodulatory protein, called the progesterone induced blocking factor (PIBF) to allow spread of the cancer. Support for this concept has been provided by cancer cell line studies showing that PIBF is produced by these cancer cells and mifepristone suppresses this protein and inhibits proliferation of these cells. Furthermore, controlled murine studies with several spontaneous different types of cancer showed a clear beneficial effect of mifepristone over placebo control. Finally, there have been a variety of anecdotal reports showing efficacy of mifepristone in providing increased length and quality of life in patients with different types of advanced cancers., Case Report: Single agent mifepristone was found to provide significant palliative benefit for a 51-year-old male whose metastatic advanced fibroblastic osteosarcoma progressed despite surgery, radiotherapy, multiagent chemotherapy, and targeted therapy., Conclusion: Thus, osteosarcoma can be added to the list of cancers, not necessarily associated with the classic nuclear progesterone receptor, that seem to respond to progesterone receptor antagonist therapy., (Copyright © 2021 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
39. Treatment With Mifepristone Allows a Patient With End-stage Pancreatic Cancer in Hospice on a Morphine Drip to Restore a Decent Quality of Life.
- Author
-
Check JH, Check D, Srivastava MD, Poretta T, and Aikins JK
- Subjects
- Analgesics, Opioid pharmacology, Hormone Antagonists pharmacology, Humans, Male, Middle Aged, Mifepristone pharmacology, Morphine pharmacology, Pancreatic Neoplasms mortality, Pancreatic Neoplasms pathology, Survival Analysis, Analgesics, Opioid therapeutic use, Hormone Antagonists therapeutic use, Mifepristone therapeutic use, Morphine therapeutic use, Pancreatic Neoplasms drug therapy, Quality of Life psychology
- Abstract
Background: There is evidence that a unique immunomodulatory protein, known as the progesterone induced blocking factor (PIBF), is utilized by a large variety of cancers to escape immune surveillance. Mifepristone, a progesterone receptor antagonist/modulator, anecdotally, has been found to increase both length and quality of life in many different types of advanced cancers., Case Report: Though there was one previous case of pancreatic cancer that showed a significant reduction in pain for the one month she took mifepristone before changing to an experimental drug, the case presented here provided much greater evidence that this drug can markedly improve both length and quality of life, in at least some patients, with very advanced pancreatic cancer., Conclusion: It is hoped that this case report will influence others to prescribe mifepristone off-label and hopefully substantiate this finding of marked palliative benefit in the majority of a larger series of patients., (Copyright © 2020 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
40. Therapy Aimed to Suppress the Production of the Immunosuppressive Protein Progesterone Induced Blocking Factor (PIBF) May Provide Palliation and/or Increased Longevity for Patients With a Variety of Different Advanced Cancers - A Review.
- Author
-
Check JH and Check D
- Subjects
- Animals, Female, Hormone Antagonists therapeutic use, Humans, Killer Cells, Natural immunology, Longevity, Mifepristone therapeutic use, Neoplasms immunology, Palliative Care, Placenta immunology, Pregnancy, Pregnancy Proteins immunology, Progesterone pharmacology, Progestins pharmacology, Receptors, Progesterone metabolism, Suppressor Factors, Immunologic immunology, Neoplasms drug therapy, Pregnancy Proteins antagonists & inhibitors, Suppressor Factors, Immunologic antagonists & inhibitors
- Abstract
Progesterone induced blocking factor (PIBF) is a unique protein that is not present in normal cells, but is found predominantly in rapidly growing cells of the fetal placental unit or cancer cells. There is a larger "parent" form that is a nuclear protein involved in cell to cell regulation, allowing tumor cells to proliferate and invade tissues. The parent compound is cleaved into smaller intracytoplasmic isoforms that can suppress cellular immune response, especially, but not limited to natural killer cells. The progesterone receptor antagonist mifepristone can suppress messenger RNA for PIBF, but can also suppress the intracytoplasmic protein. Treating cancer cell lines, intact animals with a variety of spontaneous cancers, and people with various cancers with mifepristone, has been found to inhibit cancer growth, and provide both palliation of symptoms and longevity possibly by suppressing this unique immunomodulatory protein., (Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
41. Mifepristone Extends Both Length and Quality of Life in a Patient With Advanced Non-small Cell Lung Cancer that Has Progressed Despite Chemotherapy and a Check-point Inhibitor.
- Author
-
Check JH, Check D, and Poretta T
- Subjects
- Adenocarcinoma of Lung immunology, Adenocarcinoma of Lung pathology, Aged, B7-H1 Antigen antagonists & inhibitors, B7-H1 Antigen immunology, Carcinoma, Non-Small-Cell Lung immunology, Carcinoma, Non-Small-Cell Lung pathology, Disease Progression, Female, Humans, Lung Neoplasms immunology, Lung Neoplasms pathology, Neoplasm Staging, Time Factors, Treatment Outcome, Adenocarcinoma of Lung drug therapy, Antineoplastic Agents, Immunological therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Carcinoma, Non-Small-Cell Lung drug therapy, Lung Neoplasms drug therapy, Mifepristone therapeutic use, Nivolumab therapeutic use, Quality of Life
- Abstract
Case Report: Case 1 of an investigator-initiated study using oral single agent mifepristone to halt stage IV non-small cell lung cancer whose tumor was devoid of any targeted markers has remained ECOG zero and in good health for over 3 years. Case 2, reported here, is a 68-year-old woman with stage IV non-small cell lung cancer whose tumor was positive for the programmed death ligand-1 (PD-L1) marker. Her cancer progressed despite treatment with a check-point inhibitor (nivolumab), besides 3 rounds of multi-agent chemotherapy. After 1 ½ years of treatment with single agent mifepristone, her cancer remains stable (even some tumor regression) and her quality of life is only impaired by her pre-existing chronic obstructive lung disease, not her cancer., Conclusion: Mifepristone therapy may provide a method to halt metastatic lung cancer positive for the PD-L1 marker when check-point inhibitors are no longer effective., (Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
42. The role of progesterone and the progesterone receptor in cancer.
- Author
-
Check JH
- Abstract
Introduction: There is an abundance of accumulating data strongly suggesting there is a key role for the progesterone receptor in the molecular events effecting the growth or containment of a variety of cancers. This knowledge should lead to novel new strategies to combat various cancers, including drugs classified as progesterone receptor modulators or monoclonal antibodies against some of the key proteins needed for cancer proliferation by suppressing immune surveillance. Areas covered: The role of the classic nuclear receptor and molecular events needed for proliferation are reviewed including cancers of the breast, endometrium, prostate, thyroid, and leiomyomas and leiomyosarcoma. The potential role of non-genomic membrane progesterone receptors is reviewed. The prognostic role of the presence of progesterone receptors is also discussed. Over 1000 research publications were read after conducting a PubMed search. Expert commentary: Discussion is made about a unique immunomodulatory protein called the progesterone induced blocking factor (PIBF). The role of this protein, that is unique to rapidly growing cells, may hold a key to how the cancer cells escape immune surveillance. Thus, techniques to suppress the intracytoplasmic isoforms of PIBF may play a significant role in the fight against all cancers, not just the ones with the classic nuclear progesterone receptors.
- Published
- 2017
- Full Text
- View/download PDF
43. Sympathetic neural hyperalgesia edema syndrome as a cause of autoimmune hearing loss.
- Author
-
Check JH
- Subjects
- Adult, Autoimmune Diseases diagnosis, Autoimmune Diseases drug therapy, Central Nervous System Stimulants therapeutic use, Dextroamphetamine therapeutic use, Edema diagnosis, Female, Hearing Loss drug therapy, Humans, Hyperalgesia diagnosis, Syndrome, Autoimmune Diseases complications, Autonomic Nervous System Diseases complications, Edema etiology, Hearing Loss etiology, Hyperalgesia etiology
- Abstract
Purpose: To describe another previous unreported manifestation of the sympathetic neural hyperalgesia edema syndrome - autoimmune hearing loss., Materials and Methods: Dextroamphetamine sulfate 30 mg extended release capsules was given to a woman to try to help her conceive since, with her pelvic pain, chronic fatigue syndrome, and diarrhea, it was thought that an inflammatory condition related to permeation of unwanted chemicals into endometrial tissue related to the sympathetic neural hyperalgesia edema syndrome could be inhibiting her failure from conceiving despite three cycles of embryo transfer., Results: Not only did the symptoms mentioned above disappear, but she also noted marked improvement of hearing loss that had been present for several years. The improvement in hearing was documented by audiology tests and had not responded to many months of 15 mg/day prednisone., Conclusions: Autoimmune hearing loss (diagnosis established by her ear nose and throat specialist) should be added to the long list of manifestation of the sympathetic neural hyperalgesia edema syndrome.
- Published
- 2017
44. The correlation of the degree of abnormal sperm morphology using strict criteria and pregnancy rates following intrauterine insemination (IUI).
- Author
-
Check JH and Bollendorf A
- Subjects
- Adult, Female, Fertilization in Vitro, Humans, Male, Parturition, Pregnancy, Pregnancy Rate, Retrospective Studies, Statistics as Topic, Infertility, Female therapy, Insemination, Artificial, Homologous methods, Spermatozoa pathology
- Abstract
Objective: To determine the effect of extremely low sperm morphology on pregnancy rates following intrauterine insemination (IUI) where all other semen parameters were normal., Materials and Methods: Retrospective review of all IUI cycles over a two-year period on infertile women age ≤ 35 where all parameters, but morphology had to be normal. The data were evaluated according to seven levels of percentage of normal morphology (NM): 0, 1, 2, 3, 4, 5, and ≥ 6%., Results: The percent live delivery was 9.5, 16.7, 8.8, 16.1, 11.4, 12.3, and 10.9%., Conclusions: Morphology of 0% or 1% did not seem to impair pregnancy rates following IUI. More studies are needed but should include determining the confounding effect of the type of morphologic abnormality.
- Published
- 2017
45. A normal baby is possible despite twins following a single embryo transfer even if one twin is genetically defective.
- Author
-
Check JH
- Subjects
- Amniocentesis methods, Clinical Decision-Making, Down Syndrome diagnosis, Down Syndrome genetics, Female, Gestational Age, Humans, Karyotyping methods, Male, Pregnancy, Twins, Monozygotic genetics, Pregnancy Reduction, Multifetal methods, Single Embryo Transfer methods, Twins, Dizygotic genetics
- Abstract
Purpose: To demonstrate that it is important to consider all possibilities when confronted with a decision to terminate a pregnancy because it is likely to be chromosomally abnormal., Materials and Methods: A cell free DNA test was performed on a woman with dichorionic diamniotic twins that followed the transfer of a single embryo., Results: The cell free DNA test was consistent with trisomy 21. Two perinatologists favored identical twins and thus suggested termination since both twins would be trisomy 21 and the couple did not want to raise a child with Down's syndrome. Our group suggested the possibility that these were fraternal twins with one occurring from natural conception. We suggested to forego termination by D&E but to undergo an amniocentesis at 16 weeks. One twin had obvious cardiac abnormalities by ultrasound and this one was reduced while amniocentesis with karyotype was performed on fetus 2. The results showed a normal male., Conclusions: One should consider all possibilities before suggesting termination of a very desired pregnancy. This woman had also been advised by other specialists in reproductive endocrinology that conception with her own oocytes (as did occur here) was not possible and she should consider donor oocytes based on her marked diminished oocyte reserve.
- Published
- 2017
46. Dextroamphetamine sulfate provided quick relief of severe post-partum depression that was recalcitrant to standard antidepressants and psychotherapy.
- Author
-
Check JH and Jaffe A
- Subjects
- Adult, Central Nervous System Stimulants administration & dosage, Depression, Postpartum diagnosis, Drug Resistance, Fatigue drug therapy, Female, Humans, Migraine Disorders drug therapy, Psychological Techniques, Treatment Outcome, Antidepressive Agents therapeutic use, Depression, Postpartum therapy, Dextroamphetamine administration & dosage, Psychotherapy methods
- Abstract
Purpose: To determine if dextroamphetamine sulfate could improve symptoms of post-partum depression., Materials and Methods: A woman with severe post-partum depression that was resistant to standard antidepressant therapy and psychotherapy was treated with dextroamphetamine sulfate extended release capsules 15 mg/day., Results: A quick and complete abrogation of the depression ensued along with improvement of migraine headaches, insomnia, and chronic fatigue., Conclusions: Dextr6amphetamine sulfate should be considered as a treatment modality for post-partum depression.
- Published
- 2017
47. Serum levels of the immunomodulatory protein, the progesterone induced blocking factor (PIBF) which is found in high levels during pregnancy is not higher in women with progesterone (P) receptor (R) positive vs. negative breast cancer.
- Author
-
Check JH, Rosenberg A, Check DL, DiAntonio A, Rui H, Cohen R, and DiAntonio G
- Subjects
- Adult, Female, Follicular Phase physiology, Humans, Immunologic Factors blood, Pregnancy, Receptors, Estrogen metabolism, Reproducibility of Results, Breast Neoplasms blood, Pregnancy Complications, Neoplastic blood, Pregnancy Proteins blood, Receptors, Progesterone blood, Suppressor Factors, Immunologic blood
- Abstract
Purpose: To determine if serum levels of the immunomodulatory protein, the progesterone induced blocking factor (PIBF), which is present in high levels during normal pregnancy, is present in higher levels in women with breast cancer positive for progesterone receptors. The study would also determine whether the presence or absence of the estrogen receptor in any way modifies PIBF expression., Materials and Methods: PIBF using a research ELISA was evaluated in the follicular phase in 21 women with receptor status as follows: seven with estrogen receptor (ER)+ and progesterone receptor (PR)+, seven with ER- and PR+, and seven with ER+ and PR., Results: The results showed no differences in serum PIBF in the three groups. The serum PIBF levels were no different than historical controls in the follicular phase., Conclusions: Measurement of serum PIBF does not seem to be an important marker to use to either detect women with breast cancer or to help determine tumor virulence or potential specific therapies. If PIBF plays a role in helping cancer cells to escape immune surveillance, it seems that the intracytoplasmic PIBF would be the form most likely operative.
- Published
- 2017
48. Influence of the conclusion of a recent large cooperative study in changing standard protocol of inducing menses in anovulatory women with oligomenorrhea prior to initiating ovulation induction with anti-estrogens and outcome.
- Author
-
Check JH, Liss JR, and Check D
- Subjects
- Adult, Estrogens pharmacology, Female, Fertility Agents, Female therapeutic use, Humans, Letrozole, Polycystic Ovary Syndrome drug therapy, Pregnancy, Pregnancy Rate, Anovulation drug therapy, Clomiphene therapeutic use, Endometrium drug effects, Endometrium pathology, Estrogen Antagonists therapeutic use, Nitriles therapeutic use, Oligomenorrhea drug therapy, Ovulation Induction methods, Triazoles therapeutic use
- Abstract
Purpose: To compare pregnancy rates following ovulation induction in anovulatory women with clomiphene citrate vs. letrozole and to determine the relative confounding effect of inducing menses or not. The study also evaluated whether starting these anti-estrogen drugs later in the menstrual cycle has-less adverse effect on endometrial thickness., Materials and Methods: Prospective series with choice by physician of inducing menses or not or choosing clomiphene citrate or letrozole for ovulation induction. Peak endometrial thickness was compared between drugs and between those conceiving or not., Results: There were 21 first cycles using letrozole and 42 using clomiphene. Menses were not induced in 18/21 (86%) letrozole cycles and 24/42 (57%) clomiphene cycles. Clinical pregnancies occurred in four (22.2%) letrozole cycles without induced menses with one miscarriage vs. 4/24 (16.6%) clomiphene cycles, no mis- carriage. One of three (33.3%) letrozole cycles with menses induced achieved a clinical pregnancy vs. only 1/18 (5.5%) of clomiphene cycles. There were no miscarriages., Conclusions: Though the endometrial thickness was higher with clomiphene without induced menses vs. menses induced (11 mm vs. 9.5 mm), one cannot explain the trend for lower pregnancy rates in women with induced menses because of thinner endometria since the thickness was 10.3 mm for clomiphene and 10.0 with letrozole.
- Published
- 2017
49. Long-term High-quality Survival with Single-agent Mifepristone Treatment Despite Advanced Cancer.
- Author
-
Check JH, Check D, Wilson C, and Lofberg P
- Subjects
- Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Carcinoma, Renal Cell drug therapy, Hormone Antagonists therapeutic use, Kidney Neoplasms drug therapy, Lung Neoplasms drug therapy, Mifepristone therapeutic use, Neoplasms drug therapy, Survival Rate
- Abstract
Case Report: We show long-term high-quality survival following single-agent treatment with a progesterone receptor antagonist in two cases of advanced metastatic cancer. Because no biopsy was performed (patient refused) the exact type of lung cancer was not determined but the majority of oncologists who evaluated the patient thought that the rapid onset and syndrome of inappropriate anti-diuretic hormone was more consistent with small-cell lung cancer. The US Food and Drug Association granted a compassionate-use investigational new drug approval for use of single-agent 200 mg mifepristone orally/day to a moribund woman with never-treated metastatic lung cancer and a male with bilateral renal cell carcinoma who had undergone only a unilateral hemi-nephrectomy. Both had long-term high-quality survival (5 years for the patient with lung cancer with complete remission of all lung lesions, and 12 years for the male patient with kidney cancer). Neither patient had any side-effects from mifepristone therapy., Conclusion: These cases helped influence the US Food and Drug Association in granting an investigator-initiated investigational new drug study on advanced non-small cell lung cancer., (Copyright© 2016 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
50. Hypofunction of the Sympathetic Nervous System as a Possible Etiologic Cause of Recurrent Aphthous Stomatitis.
- Author
-
Present SI and Check JH
- Subjects
- Adolescent, Female, Humans, Male, Recurrence, Young Adult, Central Nervous System Stimulants therapeutic use, Dextroamphetamine therapeutic use, Stomatitis, Aphthous drug therapy, Stomatitis, Aphthous etiology, Sympathetic Nervous System physiopathology
- Abstract
Recurrent aphthous stomatitis is a common disorder of the oral mucosa. The symptoms can range from a minor nuisance to severe forms that can be extremely debilitating. Two cases of chronic aphthous stomatitis are described. The patients sought help to ameliorate vasomotor symptoms. A diagnosis of sympathetic nervous system hypofunction was established. Treatment was aimed at restoring normal sympathetic function by the administration of dextroamphetamine sulfate. Since the patients have been on the amphetamine salts, neither their vasomotor symptoms nor their aphthous lesions have returned. Hypofunction of the sympathetic nervous system should be considered as a possible etiologic factor in patients with recurrent oral ulcers when not associated with known systemic diseases.
- Published
- 2016
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.